AICrete is the only recipe-as-a-service platform optimizing local materials for cleaner and more cost-efficient concrete.

Arrcus offers hyper-scale networking software that provides software-powered network transformation for the interconnected world. The company's software improves human experiences by connecting people, machines, and data, and it provides simple-to-use software that spans the infrastructure, from routers to switches to servers, allowing businesses to unify manageability and control with the ease of a single network solution that works across the entire network infrastructure and simplifies operations. Arrcus was established in 2016 in San Jose, California, by Devesh Garg.

Atmosic Technologies is a fabless semiconductor business that develops ultra-low power wireless technologies to provide perpetual battery life and the connected Internet of Things that are battery-free. The company's technology enables devices to source power from ambient energy like light, radio frequency, thermal, and kinetic sources. The company's product lineup, including the ATM2, ATM3, ATM33, and ATM34 series, supports various IoT applications such as wearables, remotes, beacons, sensors, and asset tracking.

Avicena Tech manufactures ultra-dense, ultra-low power petabit per second optical chip interconnects. It has been known for decades that optical interconnects have the potential to provide significant benefits even at lengths down to 1 millimeter and below. Silicon photonics, plasmonics, and other high-volume commercial technologies have reached a tipping point where they can be used to address critical chip-to-chip interconnect needs. Avicena’s ultra-dense, low-latency, low-cost, low-power optical interconnects revolutionize inter-chip communications and vastly improve the performance of systems that are hampered by legacy chip-to-chip interconnects.

Chkk provides an AI platform for managing the lifecycle of cloud-native software. It helps teams research, plan, validate, and automate updates and upgrades for Kubernetes infrastructure and open-source projects while reducing operational risks.

CloudFabrix is a leading provider of AIOps, observability, and IT operations automation solutions designed to modernize and simplify IT operations for enterprises. The company’s flagship platform leverages Artificial Intelligence (AI) and Machine Learning (ML) to deliver actionable insights, predictive analytics, and end-to-end automation, enabling organizations to enhance operational efficiency, reduce costs, and accelerate digital transformation. Headquartered in Silicon Valley, CloudFabrix leverages cutting-edge Gen & Agentic AI technologies to deliver data-driven insights, predictive analytics, and seamless automation for IT infrastructure and operations teams.

Concentric’s Semantic Intelligence solution delivers data risk insights across the entire inventory of sensitive documents in the cloud and on-premises. Its deep learning technology examines each document’s content and context for efficient actionable security. It scans the documents, identifies sensitive or business-critical data, evaluates the risk each document poses, and highlights critical concerns that need immediate attention. The company was founded in 2018 and is headquartered in San Jose, California.

Cynch AI is a fintech company that offers reasoning, machine learning, and generative AI to help people make financial decisions.

Espresa is the world’s first Culture Benefits® platform that includes a suite of integrated tools with a modern digital experience that people love. Supporting HR and people teams, Espresa drives workplace culture through employee experience and engagement programs such as rewards and recognition, employee resource groups, wellbeing and fitness, challenges and achievements, reimbursements and allowances, and meetups and event scheduling. Discover how Espresa makes heroes out of HR teams while engaging people, wherever they are. Espresa is headquartered in Palo Alto, California. Learn more at Espresa.com. The company was founded in 2015 and is headquartered in Palo Alto, California.

Evidently is automated clinical summarization to supercharge documentation, research, and population health.

Frore Systems develops and supplies advanced thermal management technologies for electronic systems that require efficient heat dissipation without conventional cooling mechanisms. The company’s product portfolio includes AirJet, a solid-state active cooling chip used in consumer devices, industrial embedded systems, edge AI platforms, and IoT hardware to remove heat silently and support compact designs without fans or moving parts. It also produces LiquidJet, a direct-to-chip liquid cooling plate designed for high-performance computing environments such as data centers to address heat removal challenges for modern GPUs and AI workloads. Frore’s technologies aim to replace or augment traditional heat sinks and fans by integrating semiconductor manufacturing techniques into thermal solutions that fit into thinner, lighter, and more rugged device architectures. Its cooling systems are configured to match specific power maps of processors and deliver thermal performance improvements that enable hardware to sustain higher throughput under workload stress.

GEn1E Lifesciences is a clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare and inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in approximately 2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals and biotech industry. With approximately 90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from Y Combinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.